FDA Grants Orphan Drug Designation to PTX-252 for AML
The FDA has granted an orphan drug designation to PTX-252 for the treatment of patients with acute myeloid leukemia.
Henno Welgemoed Stijn Van Rompay Ivo Timmermans Hyloris Pharmaceuticals Van Rompay Pleco Therapeutics
Source: onclive.com